Could a probiotic cocktail delay Parkinson's? new trial launches

NCT ID NCT07619560

Recruiting now Disease control Sponsor: Taipei Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a daily supplement containing a specific probiotic, tryptophan, and branched-chain amino acids can slow the progression of early-stage Parkinson's disease. Researchers will recruit 120 participants and randomly assign them to receive either the supplement or a placebo for 12 weeks. The goal is to see if the cocktail improves motor, cognitive, and non-motor symptoms, and to build a model that predicts individual disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Probiotic Y7, tryptophan, and branched-chain amino acids (valine, leucine, isoleucine)
What this could lead to: If it works, this could point toward a simple dietary supplement that slows Parkinson's progression and improves motor and cognitive function.
What could go wrong: This is an early-stage trial with only 120 participants over 12 weeks. The supplement may show no benefit, and results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GUT MICROBIOTA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GUT MICROBIOTA PARKINSON DISEASE (PD) PROBIOTIC

Contacts and locations

Locations

Taipei Medical University Hospital
RECRUITING

Taipei, 110, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.